Mark R Charbonneau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9524040/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and <i>in silico</i> simulations of enteric hyperoxaluria. Molecular Systems Biology, 2022, 18, e10539.	7.2	16
2	Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip. Nature Communications, 2021, 12, 2805.	12.8	40
3	Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nature Metabolism, 2021, 3, 1125-1132.	11.9	72
4	Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria. Communications Biology, 2021, 4, 898.	4.4	10
5	DevelopingÂa new class of engineered live bacterial therapeutics to treat human diseases. Nature Communications, 2020, 11, 1738.	12.8	214
6	An engineered <i>E. coli</i> Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Science Translational Medicine, 2019, 11, .	12.4	242
7	A microbial perspective of human developmental biology. Nature, 2016, 535, 48-55.	27.8	215
8	Childhood undernutrition, the gut microbiota, and microbiota-directed therapeutics. Science, 2016, 352, 1533-1533.	12.6	183
9	Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children. Science, 2016, 351, .	12.6	580
10	Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in Models of Infant Undernutrition. Cell, 2016, 164, 859-871.	28.9	497
11	Cultivating Healthy Growth and Nutrition through the Gut Microbiota. Cell, 2015, 161, 36-48.	28.9	155